Development of a Plasma Biomarker for TDP-43 Proteinopathy
About This Grant
Summary Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) are neurodegenerative disorders that cause dementia and represent a major public health concern. Both diseases primarily affect the elderly and are becoming increasingly prevalent as the aging population grows. These disorders are associated with pathological changes in the brain, including the deposition of abnormal proteins. TDP-43 (TAR DNA-binding protein of 43 kDa) was initially linked to FTLD and has since been found in up to 60% of brains with AD. One of the most significant challenges in understanding the role of TDP-43 in neurodegeneration and developing effective treatments for these disorders is the lack of reliable biomarkers that can predict TDP-43 pathology in living FTLD and AD patients. TDP-43 is clinicopathologically heterogeneous, and the relationships among clinical phenotypes, local neurodegeneration, and TDP-43 pathology remain unclear. This heterogeneity arises from the complex molecular composition of TDP-43 inclusions. A biomarker or antibody capable of revealing the relationship between TDP-43 pathology and neurodegeneration would significantly advance the field. Through the screening of over 5,000 monoclonal antibodies (MAbs), we identified an anti-TDP-43 antibody, MAb No. 9, which recognizes novel TDP-43 pathology in FTLD and AD. Furthermore, Meso Scale Discovery (MSD) immunoassays using this antibody detected elevated TDP-43 levels in the plasma extracellular vesicles (EVs) of FTLD and AD patients, suggesting its potential as a plasma biomarker for TDP-43 proteinopathies across different dementias. The main objectives of this project are to investigate the MAb No. 9-positive TDP-43 pathology and its association with neurodegeneration in FTLD and AD and to develop plasma biomarkers for TDP-43 proteinopathies. To achieve these objectives, we will examine how MAb No. 9-positive TDP-43 pathology contributes to neurodegeneration in FTLD and AD by analyzing the relationships between MAb No. 9 positivity, inclusion types, pathology subtypes, and local neurodegeneration in brain specimens from autopsy- confirmed FTLD and AD patients. We will also establish plasma biomarkers of TDP-43 proteinopathies by measuring plasma EV TDP-43 levels using MSD immunoassays in cases of neuropathologically confirmed FTLD-TDP, FTLD-tau (a subtype of FTLD), and AD, as well as in healthy aging controls. This study has significant
Grant Summary
Development of a Plasma Biomarker for TDP-43 Proteinopathy is a NIA - National Institute on Aging grant providing up to $437K for university, nonprofit, healthcare org. Applications are due 2030-12-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $437K
2030-12-31
- 1Confirm your organization is eligible for Development of a Plasma Biomarker for TDP-43 Proteinopathy from NIA - National Institute on Aging, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIA - National Institute on Aging before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIA - National Institute on Aging's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of a Plasma Biomarker for TDP-43 Proteinopathy: Frequently Asked Questions
Who is eligible for the Development of a Plasma Biomarker for TDP-43 Proteinopathy?
Development of a Plasma Biomarker for TDP-43 Proteinopathy is offered by NIA - National Institute on Aging and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of a Plasma Biomarker for TDP-43 Proteinopathy provide?
Development of a Plasma Biomarker for TDP-43 Proteinopathy provides up to $437K per award from NIA - National Institute on Aging. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of a Plasma Biomarker for TDP-43 Proteinopathy deadline?
Applications for Development of a Plasma Biomarker for TDP-43 Proteinopathy are due 2030-12-31 (open). Because deadlines can change, verify the date with the funder, NIA - National Institute on Aging, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of a Plasma Biomarker for TDP-43 Proteinopathy?
To apply for Development of a Plasma Biomarker for TDP-43 Proteinopathy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIA - National Institute on Aging.